Business & Regulation

Intellectual property issues have suffocated many industry collaborations. And though IP is clearly valuable to pharma companies, there is also value in learning to let go.

A US coalition seeks lower prices for US prescription drugs, but could their proposals undermine the competitive market?

Abbott, Abbvie and Sanofi all make separate merger announcements – on the same day

What’s the best way to present a health resource? Apparently, ease of use trumps all other factors

Are you a budding biotech or pharma startup? “The Hive” could be your chance to showcase your work

Welcome to The Power List 2016

Innovation is increasingly coming from small biotechs, but such companies rely on external funding to develop the compounds. A solid regulatory strategy is essential to convince investors to fund the further development.

Sitting Down With... Christian Schneider, Director of the National Institute for Biological Standards and Control (NIBSC), UK.

The use and misuse of antibiotics is a major driver behind the drug-resistance problem, but large environmental discharges of antibiotics from pharma manufacturing can also contribute. It’s time for companies to live up to their ethical responsibilities.

Sir Andrew Witty seeks to cement his legacy as GSK addresses patents and medicines access in the developing world